Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
By Wendy L. Bennett, N. Maruthur, Sonal Singh, J. Segal, L. Wilson, Ranee Chatterjee, S. Marinopoulos, M. Puhan, P. Ranasinghe, Lauren Block and 4 more. Annals of Internal Medicine, 2011
614 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Family Practice
View Paper: https://www.semanticscholar.org/paper/b7410a5d0efed560c3b3beef263091de1e51e4fc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise (2013, background): “Current oral AHA classes often do not provide sufficiently effective or durable glycaemic control with improved βCF; although metformin provides modest weight reduction, most oral agents lead to weight gain or are weight neutral, but do not substantively reduce body weight [1,5].”
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies (2011, neutral): “However, the impact of reducing blood glucose, and the potential benefit of specific glucose-lowering agents, on CV events in patients with T2DM remains unclear and highly controversial [5,6].”
- Standards of Medical Care in Diabetes—2014 (2013, background): “Comparative effectiveness meta-analyses (114) suggest that overall, each new class of noninsulin agents added to initial therapy lowers A1C around 0.”
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “There is a sig - nificant need for high - quality comparative - effectiveness research , not only regarding glycaemic control , but also costs and those outcomes that matter most to patients— quality of life and the avoidance of morbid and life - limiting complications , especially CVD [ 19 , 23 , 7”
- Learning Optimal Individualized Treatment Rules from Electronic Health Record Data (2016, background): “Current guidelines for managing T2D advocate metformin medication as the preferred first line therapy [14], but no longer recommend a particular second-line agent largely because of insufficient evidence on the long-term outcomes of different treatments [15].”